The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae027 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Karen Sauve und 10 weiteren Autor:innen. Beteiligte Einrichtung: ContraFect Corporation, Yonkers, New York. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents, Pseudomonas aeruginosa, Microbial Sensitivity Tests. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, ContraFect Corporation, Lundquist Institute.
Abstract (Originalsprache)
Background
Lysins (cell wall hydrolases) targeting gram-negative organisms require engineering to permeabilize the outer membrane and access subjacent peptidoglycan to facilitate killing. In the current study, the potential clinical utility for the engineered lysin CF-370 was examined in vitro and in vivo against gram-negative pathogens important in human infections.
Methods
Minimum inhibitory concentration (MICs) and bactericidal activity were determined using standard methods. An in vivo proof-of-concept efficacy study was conducted using a rabbit acute pneumonia model caused by Pseudomonas aeruginosa.
Results
CF-370 exhibited potent antimicrobial activity, with MIC50/90 values (in µg/mL) for: P aeruginosa, 1/2; Acinetobacter baumannii, 1/1; Escherichia coli, 0.25/1; Klebsiella pneumoniae, 2/4; Enterobacter cloacae 1/4; and Stenotrophomonas maltophilia 2/8. CF-370 furthermore demonstrated bactericidal activity, activity in serum, a low propensity for resistance, anti-biofilm activity, and synergy with antibiotics. In the pneumonia model, CF-370 alone decreased bacterial densities in lungs, kidneys, and spleen versus vehicle control, and demonstrated significantly increased efficacy when combined with meropenem (vs either agent alone).
Conclusions
CF-370 is the first engineered lysin described with potent broad-spectrum in vitro activity against multiple clinically relevant gram-negative pathogens, as well as potent in vivo efficacy in an animal model of severe invasive multisystem infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ContraFect Corporation, Yonkers, New York.
- The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California.
- Geffen School of Medicine, University of California, Los Angeles.
ORCID-Profile: Raymond Schuch
Förderung
- Wellcome Trust
- ContraFect Corporation
- Lundquist Institute
Zitieren
APA
Sauve, K., Watson, A., Oh, J. T., Swift, S., Vila-Farres, X., Abdelhady, W., Xiong, Y. Q., LeHoux, D., Woodnutt, G., Bayer, A. S., & Schuch, R. (2024). The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae027
Vancouver
Sauve K, Watson A, Oh JT, Swift S, Vila-Farres X, Abdelhady W, et al. The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae027
BibTeX
@article{Sauve2024,
author = {Sauve, Karen and Watson, Aubrey and Oh, Jun T and Swift, Steven and Vila-Farres, Xavier and Abdelhady, Wessam and Xiong, Yan Q and LeHoux, Dario and Woodnutt, Gary and Bayer, Arnold S and Schuch, Raymond},
title = {The Engineered Lysin CF-370 Is Active Against Antibiotic-Resistant Gram-Negative Pathogens In Vitro and Synergizes With Meropenem in Experimental Pseudomonas aeruginosa Pneumonia},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae027}
}
EUVIMED